Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-08-23

Clinical Trial Update: VivaGel™ in Healthy Young Women [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of VivaGel in healthy young women to assess safety/tolerability for preventing HSV-2 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VivaGel (SPL7013)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Herpes Simplex II | Phase 1 | Status: COMPLETED